U.S. markets open in 2 hours 30 minutes
  • S&P Futures

    3,666.50
    -0.75 (-0.02%)
     
  • Dow Futures

    29,844.00
    -24.00 (-0.08%)
     
  • Nasdaq Futures

    12,480.25
    +26.00 (+0.21%)
     
  • Russell 2000 Futures

    1,835.80
    -1.70 (-0.09%)
     
  • Crude Oil

    45.00
    -0.28 (-0.62%)
     
  • Gold

    1,844.80
    +14.60 (+0.80%)
     
  • Silver

    24.31
    +0.23 (+0.93%)
     
  • EUR/USD

    1.2133
    +0.0018 (+0.15%)
     
  • 10-Yr Bond

    0.9480
    0.0000 (0.00%)
     
  • Vix

    20.91
    +0.14 (+0.67%)
     
  • GBP/USD

    1.3442
    +0.0066 (+0.50%)
     
  • USD/JPY

    104.2700
    -0.1540 (-0.15%)
     
  • BTC-USD

    19,366.90
    +417.65 (+2.20%)
     
  • CMC Crypto 200

    380.70
    +15.79 (+4.33%)
     
  • FTSE 100

    6,472.51
    +9.12 (+0.14%)
     
  • Nikkei 225

    26,809.37
    +8.39 (+0.03%)
     

Jazz: 3Q Earnings Snapshot

·1 min read

DUBLIN (AP) _ Jazz Pharmaceuticals PLC (JAZZ) on Monday reported third-quarter earnings of $148.2 million.

On a per-share basis, the Dublin-based company said it had net income of $2.64. Earnings, adjusted for amortization costs and stock option expense, came to $4.31 per share.

The results beat Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $4.03 per share.

The drugmaker posted revenue of $600.9 million in the period, also surpassing Street forecasts. Seven analysts surveyed by Zacks expected $573.9 million.

Jazz expects full-year earnings in the range of $12.20 to $13 per share, with revenue in the range of $2.32 billion to $2.38 billion.

Jazz shares have declined slightly more than 1% since the beginning of the year. In the final minutes of trading on Monday, shares hit $147.25, a climb of 17% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on JAZZ at https://www.zacks.com/ap/JAZZ